Circulation
-
Randomized Controlled Trial Multicenter Study Comparative Study
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
The morbidity and mortality of patients with functional mitral regurgitation (MR) remain high, but no pharmacological therapy has been proven effective. The hypothesis of this study was that sacubitril/valsartan would be superior to valsartan alone in improving functional MR via dual inhibition of the renin-angiotensin system and neprilysin. ⋯ URL: https://www.clinicaltrials.gov . Unique identifier: NCT02687932.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk.
In patients with severe aortic stenosis (AS) at intermediate surgical risk, treatment with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) results in similar rates of death or stroke at 2 years. Whether TAVR is cost-effective compared with SAVR for intermediate-risk patients remains uncertain. ⋯ URL: https://www.clinicaltrials.gov . Unique identifier: NCT01314313.
-
Randomized Controlled Trial Comparative Study
A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN).
Both radiofrequency and ultrasound endovascular renal sympathetic denervation (RDN) have proven clinical efficacy for the treatment of hypertension. We performed a head-to-head comparison of these technologies. ⋯ URL: https://www.clinicaltrials.gov . Unique identifier: NCT02920034.
-
Randomized Controlled Trial Multicenter Study
Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.
Obesity is thought to increase renal hyperfiltration, thereby increasing albuminuria and the progression of renal disease. The effect of pharmacologically mediated weight loss on renal outcomes is not well-described. Lorcaserin, a selective serotonin 2C receptor agonist that promotes appetite suppression, led to sustained weight loss without any increased risk for major adverse cardiovascular (CV) events in the CAMELLIA-TIMI 61 trial (Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61). ⋯ URL: https://www.clinicaltrials.gov . Unique identifier: NCT02019264.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study.
The MOMENTUM 3 study (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) has demonstrated that the HeartMate 3 (HM3) pump is associated with reduced strokes compared with the HeartMate II (HMII) device. We now perform a comprehensive analysis of stroke events to evaluate their longitudinal occurrence, clinical correlates, patterns, and impact on outcome across the 2-year duration of support. ⋯ URL: https://www.clinicaltrials.gov/ . Unique identifier: NCT02224755.